SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial
Yannis Metaxas(Kantonsspital Graubünden), Roger von Moos(Kantonsspital Graubünden), Christine Waibel(Kantonsspital Baden), Martina Schneider(Valneva (Austria)), Federica Grosso(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), M. Frueh(Kantonsspital St. Gallen), Giovanni Luca Ceresoli(Humanitas Gavazzeni), Paolo Andrea Zucali(Humanitas University), Michael Mark(Kantonsspital Graubünden), Matteo Perrino(IRCCS Humanitas Research Hospital), Annalisa Roveta(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Patrizia Froesch(Institute of Oncology Research), Christina Appenzeller(Kantonsspital St. Gallen), Schuyler Schmidt(Kantonsspital St. Gallen), E.I. Eboulet(Swiss Group For Clinical Cancer Research), Daniel Rauch(Washington University in St. Louis), C. Biaggi Rudolf(Swiss Group For Clinical Cancer Research), Miklos Pless(Ontario Institute for Cancer Research)
Cited by 2
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
|Journal of Clinical Oncology|2017|357